Shares of drugmaker Glenmark Pharmaceuticals increased as much as 2.03% to an intraday high of ₹2,214.80 apiece in early trade on the National Stock Exchange (NSE) on Monday, March 16. However, the stock slipped into the negative territory soon after.
The price increase followed the company's announcement that its North American subsidiary, Glenmark Pharmaceuticals Inc., USA (Glenmark), would launch Potassium Phosphates Injection USP in bulk package vials.
The stock was trading 0.66% lower at ₹2,156.40 per equity share, at around 10:58 AM.
The scrip gained more than 4% in the past week and about 9% over the month. On a year-to-date basis, it has advanced 9%.
While the share hit a 52-week high of ₹2,297.90 on March 11, 2026, it touched a year's low of ₹1,336 per unit on April 17, 2025.
Recent development
In a regulatory filing, the drug manufacturer stated that it will launch potassium phosphates injection USP, 15 mmol P / 22 mEq K per 5 mL and 45 mmol P / 66 mEq K per 15 mL, as single-dose vials, and 150 mmol P / 220 mEq K per 50 mL as pharmacy bulk package vials.
It added that it will begin distributing the injection in the United States in March 2026.
The firm noted that its injection is bioequivalent and therapeutically equivalent to the listed drug, Potassium Phosphates Injection USP, 15 mmol P / 22 mEq K per 5 mL, 45 mmol P / 66 mEq K per 15 mL, and 150 mmol P / 220 mEq K per 50 mL, from Fresenius Kabi.
It said that the Potassium Phosphates Injection USP, 15 mmol P / 22 mEq K per 5 mL, 45 mmol P / 66 mEq K per 15 mL, and 150 mmol P / 220 mEq K per 50 mL market (including brands and all therapeutic equivalents) achieved annual sales of approximately $50.7 million for the 12 months ending January 2026, Glenmark said, citing sales data from IQVIA.
Commenting on the development, Marc Kikuchi, President & Business Head, North America, said: "We look forward to growing our portfolio of products within the institutional channel with the upcoming launch of Potassium Phosphates Injection USP, 15 mmol P / 22 mEq K per 5 mL and 45 mmol P / 66 mEq K per 15 mL Single-Dose Vials and 150 mmol P / 220 mEq K per 50 mL Pharmacy Bulk Package Vials. We continue to strengthen our commitment to bring quality and affordable alternatives to market for patients in need with each injectable launch."
In a separate regulatory filing dated March 4, the company's Switzerland-based subsidiary, Glenmark Specialty SA, received final approval for Fluticasone Propionate Inhalation Aerosol USP, 44 mcg per actuation from the United States Food & Drug Administration (U.S. FDA).
Glenmark Pharmaceutical has a total market capitalisation of ₹61,378.68 crore, as of March 16, 2026, according to data on the NSE.
source: Upstox, Dailyhunt
No comments:
Post a Comment